Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARDELYX, INC. Board/Management Information 2015

Dec 15, 2015

32003_rns_2015-12-15_e1d6619d-24f5-47d9-b4ec-07a84d286330.zip

Board/Management Information

Open in viewer

Opens in your device viewer

8-K 1 d84917d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 10, 2015

ARDELYX, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-36485 26-1303944
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

34175 Ardenwood Blvd.

Fremont, CA 94555

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (510) 745-1700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

On December 10, 2015, Peter G. Schultz, Ph.D., notified the Board of Directors of Ardelyx, Inc. (the “ Company ”) of his decision to resign from the Board and the Compensation Committee of the Board, effective immediately, due to outside obligations. Dr. Schultz was recently appointed to serve as Chief Executive Officer of Scripps Research Institute. Dr. Schultz’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 14, 2015
By: /s/ Mark Kaufmann
Mark Kaufmann
Chief Financial Officer